Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramipril + indapamide SR versus monotherapy in uncontrolled hypertension
2019-001030-34Phase 4Completed
- Sponsor
- Egis Pharmaceuticals PLC
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ramipril and indapamide in essential hypertension and hypertension (HTN) (3 arms), sponsored by Egis Pharmaceuticals PLC. Started Apr 2019; status: completed.
02
Drugs
ramiprilindapamide
03
Conditions
essential hypertensionhypertension (HTN)
Beyond the preview
Go deeper on 2019-001030-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001030-34.